Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy

International Journal of Psychiatry in Clinical Practice

Volumn 1, Issue SUPPL. 1, 1997, Pages

  Altamura, A C ^a   Barnas, C ^b   Bitter, I ^b   Fleischhacker, W ^b   Gaebel, W ^b   Hirsch, S ^b   Kissling, W ^b   Kufferle, B ^b   Moller, H J ^b   Naber, D ^b   Pickar, D ^b   Pullen, I ^b   Tollefson, G D ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Istituto di Clinica Psichiatrica ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002725034     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651509709024747     Document Type: Conference Paper

References (34)

1. Andreasen NC, Arndt S, Alliger R et al (1995) Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 5:341-351.
2. Liddle PF (1987) The symptoms of chronic schizophrenia: a reexamination of the positive-negative dichotomy. Br J Psychiatry 151:145-151. (Pubitemid 17102086)
3. de Leon J, Simpson GM, Peralta V (1992) Positive and negative symptoms in schizophrenia: where are the data? Biol Psychiatry 31:431-434.
4. Arndt S, Andreasen NC, Flaum M et al (1995) A longitudinal study of symptom dimensions in schizophrenia: prediction and patterns of change. Arch Gen Psychiatry 5:352-360.
5. Schooler N, Keith SJ (1993) The clinical research base for the treatment of schizophrenia. Psychopharmacol Bull 29:431-446. (Pubitemid 24206388)
6. Lieberman JA (1995) Outcome of first episode schizophrenia: the differential use of antipsychotic drugs. In Critical issues in the treatment of schizophrenia (International Academy for Biomedical and Drug Research), Florence, 10-12 March, (abstracts), 60.
7. Hirsch SR (1992) Pharmacological and psychosocial approaches in the long-term treatments of schizophrenia. In Symposium on new generation of antipsychotic drugs: no\el mechanisms of action (International Academy for Biomedical and Drug Research), Monte Carlo, 16-18 March (abstracts) 29-30.
8. Altamura AC (1992) A multidimensional (pharmacokinetic and clinical-biological approach to neuroleptic response in schizophrenia (with particular reference to drug resistance). Schizophr Res 8:187-198. (Pubitemid 23043251)
9. Kissling W, Kane JM, Barnes TRE et al (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: toward a consensus view. Berlin: Springer-Verlag.
10. Breier A, Wolkowitz OM, Doran AR et al (1987) Neuroleptic responsitivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144:1549-1555. (Pubitemid 18005549)
11. Moeller HJ (1993) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neurospychopharmacol 3:1-12.
12. Fleischhacker WW, Meise U, Gunther V et al (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 89(suppl):11-15. (Pubitemid 24199707)
13. Kane J, Honigfeld G, Singer J et al (1988) Clozapine for the treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
14. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79-91. (Pubitemid 18018573)
15. Van Putten T, Marder SR, Mintz J, Poland RE (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 149:500-505.
16. Morselli PL, Zarifian E, Cuche H et al (1980) Haloperidol plasma level monitoring in psychiatric patients. In Long-term effects of neuroleptics. (Advances in Biochemical Psychopharmacology). (eds Cattabeni F et al). 529-536. New York: Raven Press.
17. Neborsky R, Janowsky D, Munson E et al (1981) Rapid treatment of acute psychotic symptoms with high and low dose haloperidol. Arch Gen Psychiatry 38:195-199. (Pubitemid 11142772)
18. Barnes TRE, Liddle PF (1990) Evidence for the validity of negative symptoms. In Schizophrenia: positive and negative symptoms and syndromes (Vol. 24, Modern problems in pharmacopsychiatry) (ed NC Andreasen) 43-72. Basel: Karger.
19. Goldman MB, Luchins DJ (1984) Intermittent therapy and tardive dyskinesia: a literature review. Hosp Community Psychiatry 35:1215-1219. (Pubitemid 15150090)
20. Moeller HJ, Kissling W, Lang C et al (1982) Efficacy and sideeffects of haloperidol in psychotic patients: oral versus intravenous administration. Am J Psychiatry 139:1571-1575. (Pubitemid 13204455)
21. Altamura AC, Curry SH, Montgomery SA, Wiles D (1985) Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87:30-33. (Pubitemid 15242007)
22. Curry SH (1976) Metabolism and kinetics of chlorpromazine in relation to effect. In Antipsychotic drugs: pharmacokinetics and pharmacodynamics (eds G Sedvall et al) 343-352. Oxford: Pergamon Press.
23. Adler LA, Angrist B, Reiter S et al (1989) Neuroleptic-induced akathisia: a review. Psychopharmacology 97:1-11. (Pubitemid 19020374)
24. Siris SG, Mason SE, Bermanzhon PC et al (1990) Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacol Bull 26:91-94. (Pubitemid 20322252)
25. Siris SG, Bewrmanzohn PC, Gonzales A et al (1991) The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 27:331-335.
26. Goff DC, Brotman AW, Waites M et al (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 147:492-494. (Pubitemid 20107117)
27. Kramer MS, Vogel WH, Dijohnson C et al (1989) Antidepressants in 'depressed' schizophrenic inpatients. Arch Gen Psychiatry 46:922-928.
28. Altamura AC, Mauri MC, Mantero M, Brunetti M (1987) Clonazepam/ haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand 76:702-706. (Pubitemid 18021474)
29. Arana GW, Goff DC, Friedman M et al (1986) Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Pyschiatry 143:650-651. (Pubitemid 16122722)
30. Ereshefsky L, Davis CM, Harrington CA et al (1984) Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 4:138-142. (Pubitemid 14051613)
31. Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160(Suppl 17):54-59.
32. Schultz SC, Kahn EM, Baker RW, Conley RR (1990) Lithium and carbamazepine augmentation in treatment refractory schizophrenia. In The neuroleptic nonresponsiw patient: Characterization and treatment (eds B Angrist & SC Schultz) 109-136. Washington DC: American Psychiatric Press.
33. Wolkowitz OM, Rapaport MH, Pickar D (1990) Benzodiazepine augmentation of neuroleptics. In The neuroleptic nonresponsive patient: characterization and treatment (eds B Angrist & SC Schultz) 89-108. Washington DC: American Psychiatric Press.
34. Seeman MV, Lang M (1990) The role of oestrogens in schizophrenia gender differences. Schizophr Bull 16:185-194. (Pubitemid 20205356)